pharma · Major Depressive Disorder · Primary Erythromelalgia · XENE
Xenon Pharmaceuticals
Xenon Pharmaceuticals trial registry — 27 ClinicalTrials.gov studies with program phase, status, and indication context.
3650 Gilmore Way, Burnaby, BC V5G 4W8, CA HQ
397 Employees
Public company Type
XENE · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3650 Gilmore Way, Burnaby, BC V5G 4W8, CA
- Employees
- 397
- Programs
- 22
- Drugs
- 2
- Patents
- 106
Xenon Pharmaceuticals clinical trials
Registry index of 27 ClinicalTrials.gov studies linked to Xenon Pharmaceuticals programs — each row shows trial ID, program name, phase, status, and indication.
Xenon Pharmaceuticals trial registry — 27 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Xenon Pharmaceuticals.
-
XPF-008-201 — Phase 2
Clinical update -
XEN496 — Phase 3
Clinical update -
XPF-010, Placebo to match XPF-010 — Phase 3
Clinical update -
Placebo, XPF-010 — Phase 3
Clinical update -
XPF-010 — Phase 3
Clinical update -
Azetukalner — Phase 3
Clinical update -
Azetukalner — Phase 3
Clinical update -
Azetukalner — Phase 3
Clinical update
Trial registry
-
CTIS ↗ - 2025-522775-29-00CTIS ↗
Placebo, XPF-010
Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)
- 2025-522872-10-00CTIS ↗
XPF-010
Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)
-
CTIS ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗